BMS-303141

Cas No.:	943962-47-8
Chemical Name:	3,5-Dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide
Synonyms:	BMS303141;BMS-303141;3,5-dichloro-2-hydroxy-N-(4-methoxybiphenyl-3-yl)benzenesulfonamide;BMS30314;3,5-Dichloro-2-hydroxy-N-(4-methoxy[1,1′-biphenyl]-3-yl)-benzenesulfonamide;BMS 303141;3,5-dichloro-2-hydroxy-N-(4-methoxy-[1,1'-biphenyl]-3-yl)benzenesulfonamide;3,5-dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide;C19H15Cl2NO4S;AOB3947;HMS3740O11;BCP06495;BMS 30314;BDBM50209010;3497AH;AK548147
SMILES:	ClC1=C([H])C(=C([H])C(=C1O[H])S(N([H])C1=C(C([H])=C([H])C(C2C([H])=C([H])C([H])=C([H])C=2[H])=C1[H])OC([H])([H])[H])(=O)=O)Cl
Formula:	C19H15Cl2NO4S
M.Wt:	424.2977
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC50 of 0.13 μM.
In Vivo:	Chronic oral dosing of BMS-303141 in high-fat fed mice lowers approximate 20-30% plasma cholesterol and triglycerides, as well as 30-50% fasting plasma glucose. Chronic treatment with BMS-303141 shows a gradual inhibition of weight gain along with a reduction in adiposity without apparent changes in food intake. BMS-303141 shows an oral bioavailability of 55% but a relatively short half-life of 2.1 h[1].
In Vitro:	In HepG2 cells, BMS-303141 shows inhibition of total lipid syntheses with an IC50 of 8 μM. BMS-303141 shows no cytotoxicity up to 50 lM under a cell based Alamar Blue cytotoxicity assay, indicating the observed inhibition of lipid synthesis is not a result of compound-induced cytotoxicity[1].